NR565 Advanced Pharmacology Final
Exam 2026/2027 | Verified Questions and
Answers Chamberlain University College
of Nursing | MSN and NP Candidates
DISCLAIMER: This examination is prepared for educational purposes to
support NR565 Advanced Pharmacology Fundamentals exam preparation. All
pharmacological decisions should be resolved using current evidence-based
guidelines, drug information, and clinical judgment.
1. Which pharmacokinetic term describes the fraction of an
administered dose that reaches systemic circulation unchanged?
A. Volume of distribution
B. Bioavailability
C. Intrinsic efficacy
D. Therapeutic index
Answer: B
Rationale: Bioavailability is the fraction of drug reaching systemic circulation
in active form. Lehne's Pharmacotherapeutics emphasizes that oral drugs may
have reduced bioavailability because of incomplete absorption and first-pass
metabolism.
2. A drug with extensive first-pass metabolism is most likely to show
which clinical feature after oral administration?
A. Reduced systemic availability compared with an equivalent intravenous
dose
B. Complete avoidance of hepatic metabolism
C. No need for dose adjustment in liver disease
D. A guaranteed absence of drug interactions
,Answer: A
Rationale: First-pass metabolism occurs mainly in the gut wall and liver
before drug reaches systemic circulation. Extensive first-pass extraction can
lower oral bioavailability.
3. Which route of administration most reliably avoids first-pass hepatic
metabolism?
A. Oral tablet
B. Enteric-coated capsule
C. Intravenous injection
D. Swallowed liquid suspension
Answer: C
Rationale: Intravenous administration places drug directly into systemic
circulation and has 100% bioavailability. Oral products usually pass through
portal circulation before systemic distribution.
4. A highly lipophilic drug with extensive tissue binding is most likely to
have which pharmacokinetic property?
A. Low receptor affinity
B. Large volume of distribution
C. Zero elimination half-life
D. No crossing of membranes
Answer: B
Rationale: Volume of distribution rises when a drug distributes widely into
tissues rather than remaining in plasma. Lipophilicity and tissue binding
commonly increase apparent volume of distribution.
5. Two highly protein-bound drugs are prescribed together. Which issue
is most clinically relevant?
,A. They cannot be absorbed from the intestine.
B. They may compete for binding sites and increase free active drug
concentration.
C. They must both become inactive immediately.
D. They will be excreted only in bile.
Answer: B
Rationale: Only unbound drug is pharmacologically active and available for
elimination. Competition for albumin or other protein binding may increase
free drug levels, especially for narrow-therapeutic-index drugs.
6. A drug has a half-life of 12 hours. Approximately how many hours are
required for the drug to reach steady state?
A. 24 hours
B. 36 hours
C. 48 hours
D. 60 hours
Answer: D
Rationale: Steady state is typically reached after 4-5 half-lives. With a 12-
hour half-life, steady state occurs in approximately 48-60 hours (4-5 × 12
hours).
7. Which organ is primarily responsible for drug metabolism?
A. Kidney
B. Liver
C. Lungs
D. Spleen
Answer: B
Rationale: The liver is the primary organ for drug metabolism via Phase I
(CYP450 system) and Phase II (conjugation) reactions.
, 8. Which CYP450 enzyme is responsible for metabolizing the largest
number of drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
Answer: D
Rationale: CYP3A4 is the most abundant and important CYP enzyme,
metabolizing approximately 50-60% of all drugs.
9. A patient is a poor metabolizer of CYP2D6 substrates. What is the
clinical implication?
A. The patient will require higher doses of CYP2D6-metabolized drugs
B. The patient is at risk for increased drug levels and toxicity from CYP2D6
substrates
C. The patient will not respond to any medications
D. The patient has no drug interactions
Answer: B
Rationale: CYP2D6 poor metabolizers have reduced enzyme activity, leading
to higher drug levels and increased risk of toxicity for drugs metabolized by
CYP2D6.
10. What is the clinical significance of renal impairment on drug dosing?
A. No dose adjustments are needed
B. Drugs primarily excreted renally require dose reduction
C. Drugs primarily excreted renally require dose increase
D. Only drugs with narrow therapeutic index require adjustment
Answer: B
Exam 2026/2027 | Verified Questions and
Answers Chamberlain University College
of Nursing | MSN and NP Candidates
DISCLAIMER: This examination is prepared for educational purposes to
support NR565 Advanced Pharmacology Fundamentals exam preparation. All
pharmacological decisions should be resolved using current evidence-based
guidelines, drug information, and clinical judgment.
1. Which pharmacokinetic term describes the fraction of an
administered dose that reaches systemic circulation unchanged?
A. Volume of distribution
B. Bioavailability
C. Intrinsic efficacy
D. Therapeutic index
Answer: B
Rationale: Bioavailability is the fraction of drug reaching systemic circulation
in active form. Lehne's Pharmacotherapeutics emphasizes that oral drugs may
have reduced bioavailability because of incomplete absorption and first-pass
metabolism.
2. A drug with extensive first-pass metabolism is most likely to show
which clinical feature after oral administration?
A. Reduced systemic availability compared with an equivalent intravenous
dose
B. Complete avoidance of hepatic metabolism
C. No need for dose adjustment in liver disease
D. A guaranteed absence of drug interactions
,Answer: A
Rationale: First-pass metabolism occurs mainly in the gut wall and liver
before drug reaches systemic circulation. Extensive first-pass extraction can
lower oral bioavailability.
3. Which route of administration most reliably avoids first-pass hepatic
metabolism?
A. Oral tablet
B. Enteric-coated capsule
C. Intravenous injection
D. Swallowed liquid suspension
Answer: C
Rationale: Intravenous administration places drug directly into systemic
circulation and has 100% bioavailability. Oral products usually pass through
portal circulation before systemic distribution.
4. A highly lipophilic drug with extensive tissue binding is most likely to
have which pharmacokinetic property?
A. Low receptor affinity
B. Large volume of distribution
C. Zero elimination half-life
D. No crossing of membranes
Answer: B
Rationale: Volume of distribution rises when a drug distributes widely into
tissues rather than remaining in plasma. Lipophilicity and tissue binding
commonly increase apparent volume of distribution.
5. Two highly protein-bound drugs are prescribed together. Which issue
is most clinically relevant?
,A. They cannot be absorbed from the intestine.
B. They may compete for binding sites and increase free active drug
concentration.
C. They must both become inactive immediately.
D. They will be excreted only in bile.
Answer: B
Rationale: Only unbound drug is pharmacologically active and available for
elimination. Competition for albumin or other protein binding may increase
free drug levels, especially for narrow-therapeutic-index drugs.
6. A drug has a half-life of 12 hours. Approximately how many hours are
required for the drug to reach steady state?
A. 24 hours
B. 36 hours
C. 48 hours
D. 60 hours
Answer: D
Rationale: Steady state is typically reached after 4-5 half-lives. With a 12-
hour half-life, steady state occurs in approximately 48-60 hours (4-5 × 12
hours).
7. Which organ is primarily responsible for drug metabolism?
A. Kidney
B. Liver
C. Lungs
D. Spleen
Answer: B
Rationale: The liver is the primary organ for drug metabolism via Phase I
(CYP450 system) and Phase II (conjugation) reactions.
, 8. Which CYP450 enzyme is responsible for metabolizing the largest
number of drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
Answer: D
Rationale: CYP3A4 is the most abundant and important CYP enzyme,
metabolizing approximately 50-60% of all drugs.
9. A patient is a poor metabolizer of CYP2D6 substrates. What is the
clinical implication?
A. The patient will require higher doses of CYP2D6-metabolized drugs
B. The patient is at risk for increased drug levels and toxicity from CYP2D6
substrates
C. The patient will not respond to any medications
D. The patient has no drug interactions
Answer: B
Rationale: CYP2D6 poor metabolizers have reduced enzyme activity, leading
to higher drug levels and increased risk of toxicity for drugs metabolized by
CYP2D6.
10. What is the clinical significance of renal impairment on drug dosing?
A. No dose adjustments are needed
B. Drugs primarily excreted renally require dose reduction
C. Drugs primarily excreted renally require dose increase
D. Only drugs with narrow therapeutic index require adjustment
Answer: B
